The Pill Race, Where the Buyer ChangesNarrow moat
Eli Lilly (LLY) — moat facet
Oral drugs sold for cash replace the benefit manager with the patient, which changes what competing even means.
Two oral GLP-1 products now have FDA approval: Novo's Wegovy pill, cleared in December 2025, and Lilly's Foundayo, approved in April 20261. The launch trajectories have run in opposite directions recently — Wegovy pill prescriptions easing to around 163,000 from a peak near 172,000 while Foundayo climbed to 38,928 from a prior record of 34,219 — but the more consequential detail is how they are being paid for.
The majority of oral volume is flowing through cash-pay channels rather than insurance. That changes the competitive question entirely. An injectable sold through insurance competes for formulary placement, which is decided by a pharmacy benefit manager weighing rebates. A pill sold for cash competes for a patient's own money, which is decided on price, convenience and brand.
Lilly has leaned into this, pricing Foundayo for self-pay and distributing through its own platform. It is a better business in one obvious respect — no rebate is surrendered to an intermediary — and a harder one in another: cash customers are price-sensitive in a way insured patients are not, and they can stop paying at any moment.
Watch the mix of oral prescriptions between cash and insurance. If cash-pay remains the dominant channel, the incretin business is becoming a consumer products business, and should be analysed as one.
Both companies now have approved oral products and the launches are running in opposite directions month to month. What matters is not the current script counts but that a majority of oral volume is cash-pay, which turns a formulary contest into a consumer one. Lilly is well positioned for that and it is genuinely a different game — hence stable rather than widening.
Novo's Wegovy pill launched four months before Foundayo, and most oral prescriptions are paid in cash, so the race is for consumers rather than formularies. A rising share of new starts says the later entrant is winning; a falling one, that the first pill kept its lead.
Source: CNBC, Eli Lilly Q2 2026 earnings ↗- Third-party estimateNovo's Wegovy pill was approved December 2025 and Lilly's Foundayo April 2026; Wegovy pill scripts eased to ~163,000 from ~172,000 while Foundayo rose to 38,928 from 34,219, with most oral volume cash-pay.Oral GLP-1 launch tracking — two oral GLP-1 products have FDA approval, Novo Nordisk's Wegovy pill (December 2025) and Eli Lilly's Foundayo (April 2026); Wegovy pill prescriptions eased to about 163,000 from a peak near 172,000 while Foundayo rose to 38,928 from a prior record of 34,219; within eight weeks oral Wegovy captured around a third of new-to-brand prescriptions, with the majority of volume flowing through cash-pay channels — 2026 · publ. 2026 · source ↗